Tango Therapeutics (TNGX)’ treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target lowered to $8 from $16 at B. Riley
- Tango Therapeutics price target lowered to $8 from $18 at Guggenheim
- Tango Therapeutics Advances Cancer Treatment Pipeline
- Trump Media, broader market surge after Trump wins election: Morning Buzz
- Tango Therapeutics reports Q3 EPS (27c), consensus (37c)